KR20110061624A - C형 간염 항체 및 이의 용도 - Google Patents

C형 간염 항체 및 이의 용도 Download PDF

Info

Publication number
KR20110061624A
KR20110061624A KR1020117008883A KR20117008883A KR20110061624A KR 20110061624 A KR20110061624 A KR 20110061624A KR 1020117008883 A KR1020117008883 A KR 1020117008883A KR 20117008883 A KR20117008883 A KR 20117008883A KR 20110061624 A KR20110061624 A KR 20110061624A
Authority
KR
South Korea
Prior art keywords
hcv
antibody
antibodies
epitopes
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020117008883A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 퐁
젠-용 켁크
Original Assignee
더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티 filed Critical 더 보드 오브 트러스티즈 오프 더 리랜드 스탠포드 쥬니어 유니버시티
Publication of KR20110061624A publication Critical patent/KR20110061624A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C07K16/109Hepatitis C virus; Hepatitis G virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020117008883A 2008-10-05 2008-10-05 C형 간염 항체 및 이의 용도 Withdrawn KR20110061624A (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/078884 WO2010039154A1 (en) 2008-10-05 2008-10-05 Hepatitis c antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20110061624A true KR20110061624A (ko) 2011-06-09

Family

ID=42073762

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117008883A Withdrawn KR20110061624A (ko) 2008-10-05 2008-10-05 C형 간염 항체 및 이의 용도

Country Status (12)

Country Link
US (1) US8858947B2 (enExample)
EP (1) EP2331573A4 (enExample)
JP (1) JP2012504602A (enExample)
KR (1) KR20110061624A (enExample)
CN (1) CN102197050A (enExample)
AU (1) AU2008362482A1 (enExample)
BR (1) BRPI0823197A2 (enExample)
CA (1) CA2738644A1 (enExample)
EA (1) EA201170353A1 (enExample)
IL (1) IL212040A0 (enExample)
MX (1) MX2011003613A (enExample)
WO (1) WO2010039154A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034891A1 (en) * 2014-09-05 2016-03-10 Medical Research Council Anti-hepatitis c antibodies and antigen binding fragments thereof

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102596996B (zh) * 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
WO2012107589A1 (en) * 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
WO2012151263A2 (en) 2011-05-02 2012-11-08 The Johns Hopkins University A synthetic hepatitis c genome and methods of making and use
BR112015002605B1 (pt) 2012-08-07 2023-03-07 Massachusetts Institute Of Technology Agente de anticorpo específico para o vírus da dengue, seu uso, kit, composição farmacêutica e método para sua produção
CN103113458B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi34及其应用
CN103172705B (zh) * 2013-02-27 2014-08-20 北京大学人民医院 丙型肝炎病毒b细胞表位肽puhi16及其应用
RU2539770C1 (ru) * 2013-12-27 2015-01-27 Татьяна Николаевна Власик Способ нейтрализации вируса гепатита с, полностью человеческое моноклональное антитело против вируса гепатита с (варианты), композиция полностью человеческих моноклональных антител против вируса гепатита с и гибридная мышь/человек клеточная линия - продуцент полностью человеческих моноклональных антител против вируса гепатита с (варианты)
EP3104888A4 (en) 2014-02-11 2017-08-09 Massachusetts Institute Of Technology Novel full spectrum anti-dengue antibody
JPWO2015133467A1 (ja) * 2014-03-06 2017-04-06 株式会社シノテスト C型肝炎ウイルスのワクチン及び診断に用いるためのHBc/HCV E2ペプチドキメラタンパク質
CN104327170A (zh) * 2014-05-16 2015-02-04 中国疾病预防控制中心病毒病预防控制所 丙型肝炎病毒(hcv)细胞进入抑制肽zte1序列及应用
CN105254756B (zh) * 2015-11-27 2018-09-07 武汉大学 一种针对丙型肝炎病毒包膜蛋白e2的单克隆抗体及应用
WO2017162678A1 (en) * 2016-03-22 2017-09-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Humanized anti-claudin-1 antibodies and uses thereof
CN107011435B (zh) * 2016-06-01 2019-02-12 苏州银河生物医药有限公司 抗丙型肝炎病毒的全人单克隆抗体8d6
EP4095156A1 (en) * 2021-05-28 2022-11-30 Universität zu Köln Neutralizing antibodies against hepatitis c virus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1127170A4 (en) * 1998-11-05 2005-04-27 Univ Leland Stanford Junior HUMAN MONOCLONAL ANTIBODIES OF THE HEPATITIS C VIRUS (HCV) PAN
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
NZ543467A (en) * 2003-04-10 2008-07-31 Novartis Vaccines & Diagnostic The severe acute respiratory syndrome coronavirus

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016034891A1 (en) * 2014-09-05 2016-03-10 Medical Research Council Anti-hepatitis c antibodies and antigen binding fragments thereof

Also Published As

Publication number Publication date
BRPI0823197A2 (pt) 2015-06-23
CN102197050A (zh) 2011-09-21
JP2012504602A (ja) 2012-02-23
IL212040A0 (en) 2011-06-30
AU2008362482A1 (en) 2010-04-08
EP2331573A1 (en) 2011-06-15
US20120039846A1 (en) 2012-02-16
US8858947B2 (en) 2014-10-14
CA2738644A1 (en) 2010-05-08
MX2011003613A (es) 2011-08-03
EP2331573A4 (en) 2012-09-05
EA201170353A1 (ru) 2011-12-30
WO2010039154A1 (en) 2010-04-08

Similar Documents

Publication Publication Date Title
KR20110061624A (ko) C형 간염 항체 및 이의 용도
JP6993401B2 (ja) 抗ジカ(zika)ウイルス抗体およびその使用方法
Tarr et al. An alpaca nanobody inhibits hepatitis C virus entry and cell‐to‐cell transmission
US6951646B1 (en) Anti hepatitis C virus antibody and uses thereof
KR101518081B1 (ko) C형 간염 바이러스(hcv)에 대한 인간 항체 및 이것의 용도
JP5698137B2 (ja) C型肝炎ウイルス感染の阻害のためのモノクローナル抗クローディン1抗体
US7537764B2 (en) Binding molecules capable of neutralizing west nile virus and uses thereof
KR20220158053A (ko) 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단클론 항체
US20240050565A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
CN113354732A (zh) 针对埃博拉病毒糖蛋白的人抗体
EA034767B1 (ru) Человеческие антитела к белку f респираторного синцитиального вируса и способы их применения
KR20180012245A (ko) 다가 b형 간염 바이러스 항원 결합 분자 및 그의 용도
TW201242613A (en) Human antibodies to PCSK9 for use in methods of treating particular groups of subjects
CN102015767A (zh) 针对SARS-CoV的交叉中和人单克隆抗体及其使用方法
US20150118242A1 (en) Hepatitis c virus neutralizing antibody
KR20110096591A (ko) Hcv 감염의 치료적 처리 및 예방을 위한 의약으로서 항 hcv 모노클로날 항체
US20100104555A1 (en) HCV neutralizing epitopes
WO2010047829A1 (en) Mutant hepatitis c virus e2 polypeptides for hcv treatment
CN103429265A (zh) 用于治疗和预防hcv感染的抗包膜抗体和抗受体抗体组合物
US12037384B2 (en) Human monoclonal antibodies against yellow fever virus and uses therefor
WO2014065822A1 (en) Hepatitis c virus neutralizing epitopes, antibodies, and methods

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20110419

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid